CA
NZ
UK
AU
IND
US
…
Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host disease. It is also involved in the development of CYP-004, which is in Phase 3 clinical trial used for the treatment of osteoarthritis; CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds; and Diabetic Foot Ulcer which has completed phase 1 trial for the treatment of non-healing wounds on the feet/lower limbs. Further, it develops Cohort 1 which has completed Phase 1/2 for the treatment of kidney transplant. Cynata Therapeutics Limited has a license arrangement with Fujifilm corporation. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Cynata Therapeutics Limited develops allogeneic mesenchymal stem cell therapies using its Cymerus platform to produce MSCs from induced pluripotent stem cells for inflammatory and degenerative conditions. Long-term growth drivers include successful clinical development, regulatory approvals and partnering or licensing enabled by a scalable manufacturing approach that could support broader commercial supply. Investors may find the company attractive because the technology aims to deliver consistent, off-the-shelf cell products addressing unmet medical needs.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Income before tax | -9.39M | -12.06M | -14.28M | -5.45M | -7.69M |
| Net income | -9.39M | -9.74M | -14.28M | -5.45M | -7.69M |
| Selling general administrative | 3.40M | 3.21M | 3.23M | 3.99M | 4.22M |
| Selling and marketing expenses | - | - | - | 0.07M | 0.27M |
| Gross profit | 1.89M | 2.03M | - | - | - |
| Reconciled depreciation | 0.28M | 0.28M | 0.28M | 0.28M | 0.28M |
| Ebit | -9.61M | -10.23M | -14.89M | -13.84M | -9.08M |
| Ebitda | -9.33M | -9.95M | -16.26M | -13.56M | -8.80M |
| Depreciation and amortization | 0.28M | 0.28M | - | 0.28M | 0.28M |
| Operating income | -8.12M | -8.81M | -16.54M | -13.84M | -9.08M |
| Other operating expenses | 10.01M | 11.12M | 1.89M | 13.84M | 9.08M |
| Interest expense | - | - | - | 0.00M | 0.00M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | 0.23M | 0.42M | 0.35M | 0.06M | 0.09M |
| Net interest income | 0.23M | 0.42M | 0.35M | 0.06M | 0.09M |
| Income tax expense | - | -2.32M | - | -0.06M | -0.09M |
| Total revenue | 1.89M | 2.32M | - | - | - |
| Total operating expenses | 10.01M | 11.12M | - | 13.84M | 9.08M |
| Cost of revenue | - | 0.28M | - | - | - |
| Total other income expense net | -1.27M | -3.25M | 1.91M | 8.33M | 1.30M |
| Net income from continuing ops | -9.39M | -9.74M | -14.28M | -5.45M | -7.69M |
| Net income applicable to common shares | - | - | -14.28M | -5.45M | -7.69M |
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Total assets | 7.20M | 8.39M | 18.99M | 26.55M | 29.97M |
| Intangible assets | 1.85M | 1.85M | 2.13M | 2.41M | 2.69M |
| Other current assets | 0.19M | 0.22M | 0.03M | 0.03M | 0.03M |
| Total liab | 1.22M | 1.17M | 2.26M | 2.59M | 1.60M |
| Total stockholder equity | 5.98M | 7.22M | 16.73M | 23.96M | 28.37M |
| Deferred long term liab | - | - | 2.13M | 2.41M | 2.69M |
| Other current liab | 0.82M | 0.74M | - | 1.01M | 0.93M |
| Common stock | 89.52M | 81.62M | 81.62M | 74.90M | 74.90M |
| Capital stock | 89.52M | 81.62M | 81.62M | 74.90M | 74.90M |
| Retained earnings | -91.71M | -82.32M | -72.57M | -58.30M | -52.85M |
| Other assets | - | 0.00M | 2.13M | 2.41M | 2.69M |
| Cash | 5.05M | 6.21M | 16.17M | 23.80M | 26.72M |
| Total current liabilities | 1.22M | 1.17M | 2.26M | 2.59M | 1.60M |
| Net debt | -5.05M | -6.21M | - | -23.80M | -26.72M |
| Other stockholder equity | - | - | 7.68M | 7.36M | 6.32M |
| Total current assets | 5.35M | 6.54M | 16.86M | 24.14M | 27.28M |
| Net tangible assets | - | - | 16.73M | 23.96M | 28.37M |
| Net receivables | 0.10M | 0.11M | 0.34M | 0.10M | 0.28M |
| Accounts payable | 0.39M | 0.43M | 1.31M | 1.58M | 0.68M |
| Accumulated other comprehensive income | 8.17M | 7.91M | - | 7.36M | 6.32M |
| Non currrent assets other | - | -0.00M | - | - | - |
| Non current assets total | 1.85M | 1.85M | 2.13M | 2.41M | 2.69M |
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Investments | -0.05M | - | - | - | - |
| Change to liabilities | - | - | -0.26M | 0.95M | 0.74M |
| Total cashflows from investing activities | -0.05M | - | - | - | - |
| Total cash from financing activities | 7.61M | - | 6.72M | 0.21M | 18.20M |
| Change to operating activities | - | - | -0.07M | 0.03M | 0.17M |
| Net income | -9.39M | -9.74M | -14.28M | -5.45M | -7.69M |
| Change in cash | -1.16M | -9.96M | -7.63M | -2.92M | 13.07M |
| Begin period cash flow | 6.21M | 16.17M | 23.80M | 26.72M | 13.65M |
| End period cash flow | 5.05M | 6.21M | 16.17M | 23.80M | 26.72M |
| Total cash from operating activities | -8.72M | -9.96M | -14.28M | -3.30M | -5.16M |
| Issuance of capital stock | 8.14M | - | 7.04M | - | 18.31M |
| Depreciation | - | 0.28M | 0.28M | 0.28M | 0.28M |
| Change to account receivables | 0.03M | 0.36M | -0.36M | 0.02M | -0.16M |
| Sale purchase of stock | -0.52M | - | -0.32M | - | -0.57M |
| Other cashflows from financing activities | - | - | -0.32M | 0.21M | 0.46M |
| Change to netincome | - | - | 0.40M | 0.86M | 1.49M |
| Capital expenditures | 0.05M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 0.09M | -0.73M | - | - | - |
| Other non cash items | -8.81M | 0.51M | - | - | - |
| Free cash flow | -8.77M | -9.96M | -14.28M | -3.30M | -5.16M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| CYYNF Cynata Therapeutics Limited |
- -% |
0.01 | - | - | 21.11 | 21.70 | -0.88 |
| NVO Novo Nordisk A/S |
0.79 2.05% |
39.08 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
14.65 2.77% |
544.34 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
7.93 0.98% |
821.20 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
790.15 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host disease. It is also involved in the development of CYP-004, which is in Phase 3 clinical trial used for the treatment of osteoarthritis; CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds; and Diabetic Foot Ulcer which has completed phase 1 trial for the treatment of non-healing wounds on the feet/lower limbs. Further, it develops Cohort 1 which has completed Phase 1/2 for the treatment of kidney transplant. Cynata Therapeutics Limited has a license arrangement with Fujifilm corporation. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.
| Name | Title | Year Born |
|---|---|---|
| Dr. Ross Alexander MacDonald Ph.D. | MD, CEO & Exec. Director | 1958 |
| Dr. Kilian Kelly | Chief Operating Officer | NA |
| Dr. Jolanta Airey | Chief Medical Officer | NA |
| Dr. Suzanne Lipe | VP of Alliance Management | 1950 |
| Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D., MAICD | Company Sec. | 1963 |
| Dr. Kilian Kelly Ph.D. | MD, CEO & Director | NA |
| Dr. Mathias Kroll | Chief Business Officer | NA |
| Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D. | Company Secretary | 1963 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.30%
Communication Services
+0.09%
Consumer Cyclical
+1.09%
Consumer Defensive
-0.07%
Energy
-0.09%
Financial Services
+0.71%
Financials
+0.42%
Healthcare
+0.94%
Industrials
+0.74%
Real Estate
+0.54%
Technology
-0.33%
Utilities
+0.51%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...